Enzon to Begin Phase 1 Study of Novel Androgen Receptor

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the Investigational New Drug approval by the US Food and Drug Administration and plan to commence enrollment into a Phase 1a/1b study shortly.

The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer.

Unlike other novel agents for CRPC that inhibits androgen production or receptor activation, EZN-4176 is unique in its ability to eliminate androgen receptor.